Human versus Artificial Intelligence: Validation of a Deep Learning Model for Retinal Layer and Fluid Segmentation in Optical Coherence Tomography Images from Patients with Age-Related Macular Degeneration

Citations Over TimeTop 13% of 2024 papers

Abstract

Artificial intelligence (AI) models have received considerable attention in recent years for their ability to identify optical coherence tomography (OCT) biomarkers with clinical diagnostic potential and predict disease progression. This study aims to externally validate a deep learning (DL) algorithm by comparing its segmentation of retinal layers and fluid with a gold-standard method for manually adjusting the automatic segmentation of the Heidelberg Spectralis HRA + OCT software Version 6.16.8.0. A total of sixty OCT images of healthy subjects and patients with intermediate and exudative age-related macular degeneration (AMD) were included. A quantitative analysis of the retinal thickness and fluid area was performed, and the discrepancy between these methods was investigated. The results showed a moderate-to-strong correlation between the metrics extracted by both software types, in all the groups, and an overall near-perfect area overlap was observed, except for in the inner segment ellipsoid (ISE) layer. The DL system detected a significant difference in the outer retinal thickness across disease stages and accurately identified fluid in exudative cases. In more diseased eyes, there was significantly more disagreement between these methods. This DL system appears to be a reliable method for accessing important OCT biomarkers in AMD. However, further accuracy testing should be conducted to confirm its validity in real-world settings to ultimately aid ophthalmologists in OCT imaging management and guide timely treatment approaches.

Related Papers

• → Age-related macular degeneration(2023)400 cited
• → PHARMACOGENOMICS OF RESPONSE TO ANTI-VEGF THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION(2015)36 cited
• → Barriers to care in neovascular age-related macular degeneration: Current understanding, developments, and future directions(2023)8 cited
• Real-world UK NHS outcomes of a switch to Aflicercept from Ranibizumab in Neovascular age related macular degeneration (nvAMD).(2015)
• → Sub Macular Hemorrhage in Age Related Macular Degeneration(2020)